Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
State Key Laboratory of Esophageal Cancer Prevention and Treatment & Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, China.
Front Immunol. 2021 Aug 19;12:698312. doi: 10.3389/fimmu.2021.698312. eCollection 2021.
Serum autoantibodies (AAbs) against tumor-associated antigens (TAAs) could be useful biomarkers for cancer detection. This study aims to evaluate the diagnostic value of autoantibody against PDLIM1 for improving the detection of ovarian cancer (OC).
Immunohistochemistry (IHC) test in tissue array containing 280 OC tissues, 20 adjacent tissues, and 8 normal ovarian tissues was performed to analyze the expression of PDLIM1 in tissues. Enzyme-linked immunosorbent assay (ELISA) was employed to measure the autoantibody to PDLIM1 in 545 sera samples from 182 patients with OC, 181 patients with ovarian benign diseases, and 182 healthy controls.
The results of IHC indicated that 84.3% (236/280) OC tissues were positively stained with PDLIM1, while no positive staining was found in adjacent or normal ovarian tissues. The frequency of anti-PDLIM1 autoantibody was significantly higher in OC patients than that in healthy and ovarian benign controls in both training (n=122) and validation (n=423) sets. The area under the curves (AUCs) of anti-PDLIM1 autoantibody for discriminating OC from healthy controls were 0.765 in training set and 0.740 in validation set, and the AUC of anti-PDLIM1 autoantibody for discriminating OC from ovarian benign controls was 0.757 in validation set. Overall, it was able to distinguish 35.7% of OC, 40.6% of patients with early-stage, and 39.5% of patients with late-stage. When combined with CA125, the AUC increased to 0.846, and 79.2% of OC were detected, which is statistically higher than CA125 (61.7%) or anti-PDLIM1(35.7%) alone (<0.001). Also, anti-PDLIM1 autoantibody could identify 15% (18/120) of patients that were negative with CA125 (CA125 <35 U/ml).
The anti-PDLIM1 autoantibody response in OC patients was positively correlated with PDLIM1 high expression in OC tissues, suggesting that the autoantibody against PDLIM1 might have the potential to be a novel serological biomarker of OC, serving as a complementary measure of CA125, which could improve the power of OC detection.
针对肿瘤相关抗原（TAAs）的血清自身抗体（AAbs）可能是癌症检测的有用生物标志物。本研究旨在评估针对 PDLIM1 的自身抗体提高卵巢癌（OC）检测的诊断价值。
使用包含 280 例 OC 组织、20 例邻近组织和 8 例正常卵巢组织的组织阵列进行免疫组织化学（IHC）检测，以分析 PDLIM1 在组织中的表达。采用酶联免疫吸附试验（ELISA）检测 182 例 OC 患者、181 例卵巢良性疾病患者和 182 例健康对照者的 545 例血清样本中针对 PDLIM1 的自身抗体。
IHC 结果表明，84.3%（236/280）的 OC 组织呈 PDLIM1 阳性染色，而邻近组织或正常卵巢组织无阳性染色。在训练集（n=122）和验证集（n=423）中，OC 患者中抗 PDLIM1 自身抗体的频率均明显高于健康对照组和卵巢良性对照组。在训练集中，抗 PDLIM1 自身抗体区分 OC 与健康对照组的曲线下面积（AUC）为 0.765，在验证集中为 0.740，抗 PDLIM1 自身抗体区分 OC 与卵巢良性对照组的 AUC 为 0.757在验证集中。总的来说，它能够区分 35.7%的 OC、40.6%的早期患者和 39.5%的晚期患者。当与 CA125 联合使用时，AUC 增加到 0.846，79.2%的 OC 被检测到，这明显高于 CA125（61.7%）或抗 PDLIM1（35.7%）单独检测（<0.001）。此外，抗 PDLIM1 自身抗体还可以识别 120 例 CA125（CA125<35U/ml）阴性患者中的 15%（18/120）。
OC 患者的抗 PDLIM1 自身抗体反应与 OC 组织中 PDLIM1 的高表达呈正相关，提示针对 PDLIM1 的自身抗体可能具有成为 OC 新型血清生物标志物的潜力，作为 CA125 的补充检测手段，可提高 OC 的检出率。
